OPS 2071

Drug Profile

OPS 2071

Alternative Names: OPS-2071

Latest Information Update: 23 Mar 2016

Price : $50

At a glance

  • Originator Korea Otsuka Pharmaceutical; Otsuka Pharmaceutical
  • Class Anti-infectives; Quinolones
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Intestinal infections

Most Recent Events

  • 01 Jun 2015 Phase-II clinical trials in Intestinal infections in Japan (PO)
  • 01 Apr 2014 Korea Otsuka completes a phase I trial in Intestinal infections (in volunteers) in South Korea (NCT01925521)
  • 20 Aug 2013 Phase-I clinical trials in Intestinal infections (in volunteers) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top